NCT05671822 2026-02-12
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
Clinical Trials
1 trialsHER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma × Capecitabine × 90 days × Clear all